Skip to main content

Need urgent help? Start triage first, then route to emergency care.

Meds A-Z

Polysulfated Glycosaminoglycan

Detailed information about Polysulfated Glycosaminoglycan

Official label facts Owner quick guide first Marketing clearly labeled
Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

What it does:

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatm...

When it's needed:

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for huma...

Call your vet sooner if you notice:

  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Commonly reported reactions:

  • (2 reports)
  • (1 reports)
  • (1 reports)

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Talk to a Vet / Find a Vet Near You
Image coming soon
Polysulfated Glycosaminoglycan

Polysulfated Glycosaminoglycan

Drug type: Generic ingredient • Branded profile FDA branded products available

Species: Both

Manufacturer: MSK

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: MSK
Form: Liquid (Solution)
Identifiers:
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Source metadata:

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
15
Species represented
2
Most Reported Reactions
Reaction Cases Species Serious cases
2 Cat, Dog 1
1 Cat 1
1 Cat 1
1 Dog 1
1 Dog 1
1 Cat 1
1 Cat 1
1 Dog 1

Species coverage: Dog (20) Cat (12)

View detailed reaction table
Reaction Species Seriousness Frequency Reports
Dog Non-serious - 1
Dog Serious - 1
Cat Serious - 1
Cat Serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Serious - 1
Cat Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Non-serious - 1
Dog Serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Cat Non-serious - 1
Dog Non-serious - 1
Cat Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Cat Serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Dog Non-serious - 1
Source metadata:

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.
Talk to a Vet / Find a Vet Near You
Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Adequan® Canine Adequan® Injectable Adequan® i.m. Multi-Dose Adequan® i.m.
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Adults, Dog, Horse
Rx/OTC: RX
Form/route: Liquid (Solution) Intra-Articular, Intramuscular
Applications: NADA 141-038 • NADA 140-901 • NADA 136-383
Documents: 4 (FOI: 4) • SPL: 4 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 56 Cat 56 View
Case summaries: 10 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Abnormal radiograph finding (1) Anaphylaxis (1) Cardiac arrest (1) Death (1) Decreased drinking (1) Decreased haematocrit (1) Diarrhoea (1) Diarrhoea (1) Difficulty standing (1) Elevated creatinine (1) Elevated globulins (1) Elevated symmetrical dimethylarginine (SDMA) (1) Emesis (multiple) (1) Eosinopenia (1) Facial oedema (1) Falling (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Package NDC Product NDC Form / Route Status
10797-959-01 10797 -
10797-975-01 10797 -
10797-975-02 10797 -
10797-995-01 10797 -
10797-995-70 10797 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 7 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eat… (Official, 2026-02-12)
  • usage: Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal join… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Adequan® Canine
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intramuscular
American Regent, Inc. NADA 141-038 Approved Jun 28, 2018
Adequan® i.m. Multi-Dose Adequan® i.m.
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intramuscular
American Regent, Inc. NADA 140-901 Approved Dec 7, 2017
Adequan® Injectable
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) Intra-Articular
American Regent, Inc. NADA 136-383 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.
Dogs
Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary

    Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplemental application amends the NADA to provide for the use of Adequan® i.m. in the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the hock joint in horses.

  • Summary

    Adequan® i.m. is recommended for the intramuscular treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog
Digestive
Vomiting (813) Diarrhea (611)
Neurologic
Tiredness (lethargy) (347) Tiredness (lethargy) (191) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3)
Effectiveness
Lack of efficacy - NOS (450)
Other
Not eating (314) Death by euthanasia (187) Elevated alanine aminotransferase (163) Panting (4) Panting (4) Panting (4) Panting (4) Panting (4) Panting (4) Not eating (3) Not eating (3) Not eating (3) Not eating (3) Not eating (3) Not eating (3) Weight loss (3) Weight loss (3) Weight loss (3) Weight loss (3) Weight loss (3) Weight loss (3) Abnormal radiograph finding (2) Abnormal radiograph finding (2) Abnormal radiograph finding (2) Abnormal radiograph finding (2) Abnormal radiograph finding (2) Abnormal radiograph finding (2) Anaphylaxis (2) Anaphylaxis (2) Anaphylaxis (2) Anaphylaxis (2) Anaphylaxis (2) Anaphylaxis (2) Death by euthanasia (2) Death by euthanasia (2) Death by euthanasia (2) Death by euthanasia (2) Death by euthanasia (2) Death by euthanasia (2) Disorientation (2) Disorientation (2) Disorientation (2) Disorientation (2) Disorientation (2) Disorientation (2)
Cat
Digestive
Vomiting (57) Diarrhea (16) Loss of appetite (16)
Neurologic
Tiredness (lethargy) (20) Tiredness (lethargy) (18)
Effectiveness
Lack of efficacy - NOS (24)
Other
Weight loss (24) Death by euthanasia (19) Cardiac arrest (1) Cardiac arrest (1) Cardiac arrest (1) Cardiac arrest (1) Cardiac arrest (1) Cardiac arrest (1) Death (1) Death (1) Death (1) Death (1) Death (1) Death (1) Decreased haematocrit (1) Decreased haematocrit (1) Decreased haematocrit (1) Decreased haematocrit (1) Decreased haematocrit (1) Decreased haematocrit (1) Elevated creatinine (1) Elevated creatinine (1) Elevated creatinine (1) Elevated creatinine (1) Elevated creatinine (1) Elevated creatinine (1) Elevated symmetrical dimethylarginine (1) Elevated symmetrical dimethylarginine (1) Elevated symmetrical dimethylarginine (1) Elevated symmetrical dimethylarginine (1) Elevated symmetrical dimethylarginine (1) Elevated symmetrical dimethylarginine (1) General illness (1) General illness (1) General illness (1) General illness (1) General illness (1) General illness (1) Hiding (1) Hiding (1) Hiding (1) Hiding (1) Hiding (1) Hiding (1) Joint pain (1) Joint pain (1) Joint pain (1) Joint pain (1) Joint pain (1) Joint pain (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shepherd Dog - German, Male, 5.8 year, 40.82 kilogram • Drug: MSK, Unknown • Reactions: Sneezing, Listless, Not eating, Reduced responses, Difficulty standing… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055636
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.80 Year
  • Weight: 40.820 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Sneezing Listless Not eating Reduced responses Difficulty standing Falling Polyuria Decreased drinking Fever Tachycardia Tachypnoea Weight loss Stress leukogram Neutrophilia Monocytosis Eosinopenia Elevated globulins Abnormal radiograph finding Hepatomegaly Proprioception deficit Muscle atrophy Pain NOS
Outcomes: Ongoing

Cat, Cat (unknown), Female, 20.5 year • Drug: MSK, Unassigned, Unknown • Reactions: General illness, Hiding, Joint pain, Elevated creatinine, Elevated symmetrical dimethylarginine… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055646
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 20.50 Year
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
General illness Hiding Joint pain Elevated creatinine Elevated symmetrical dimethylarginine Decreased haematocrit Urinary tract infection
Outcomes: Outcome Unknown

Dog, ['Chihuahua', 'Dog (unknown)'], Male, 10.75 year, 5.715 kilogram • Drug: MSK, Solution, Subcutaneous, Dose: 0.25 mL per dose • Reactions: Anaphylaxis, Swollen face, Itching, Swollen feet • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055955
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.75 Year
  • Weight: 5.715 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Solution
  • Dose: 0.25 mL per dose
Reactions Reported:
Anaphylaxis Swollen face Itching Swollen feet
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Male, 13 year, 6.804 kilogram • Drug: MSK, Solution, Subcutaneous, Dose: 0.50 mL per dose, Frequency: 1 per week • Reactions: Nausea, Prolonged one stage prothrombin time, Prolonged activated partial thrombin time, Cardiac arrest, Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-055853
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 13.00 Year
  • Weight: 6.804 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Solution
  • Dose: 0.50 mL per dose
  • Frequency: 1 per week
Reactions Reported:
Nausea Prolonged one stage prothrombin time Prolonged activated partial thrombin time Cardiac arrest Death
Outcomes: Died

Dog, Crossbred Canine/dog, Male, 8 year, 10.569 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Shaking, Seizure NOS, Diarrhea, Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-054899
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 8.00 Year
  • Weight: 10.569 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Shaking Seizure NOS Diarrhea Vomiting
Outcomes: Recovered/Normal

Dog, Bulldog - English, Male, 6 year, 32.659 kilogram • Drug: MSK, Injection, solution, Unknown • Reactions: Partial lack of efficacy • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-053131
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 6.00 Year
  • Weight: 32.659 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Injection, solution
Reactions Reported:
Partial lack of efficacy
Outcomes: Ongoing

Dog, ['Bulldog - English', 'Retriever - Labrador'], Male, 11 year, 30.844 kilogram • Drug: MSK, Solution, Subcutaneous, Dose: 1.40 mL per dose • Reactions: Anaphylaxis, Facial oedema, Hives • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-052943
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 30.844 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Solution
  • Dose: 1.40 mL per dose
Reactions Reported:
Anaphylaxis Facial oedema Hives
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Male, 12 year, 6.35 kilogram • Drug: MSK, Parenteral • Reactions: Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-051052
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 6.350 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Parenteral
Reactions Reported:
Vomiting
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.